Document is current
Any future updates will be listed below
-
Authors
Arasada, Rajeswara Rao
Shilo, Konstantin
Yamada, Tadaaki
Zhang, Jianying
Yano, Seiji
Ghanem, Rashelle
Wang, Walter https://orcid.org/0000-0003-1054-4688
Takeuchi, Shinji
Fukuda, Koji
Katakami, Nobuyuki
Tomii, Keisuke
Ogushi, Fumitaka
Nishioka, Yasuhiko
Talabere, Tiffany
Misra, Shrilekha
Duan, Wenrui
Fadda, Paolo
Rahman, Mohammad A.
Nana-Sinkam, Patrick
Evans, Jason
Amann, Joseph
Tchekneva, Elena E.
Dikov, Mikhail M.
Carbone, David P.
- License Information
-
More Information
Article History
Received: 13 November 2017
Accepted: 2 July 2018
First Online: 10 August 2018
Change Date: 5 September 2018
Change Type: Update
Change Details: This Article was originally published without the accompanying Peer Review File. This file is now available in the HTML version of the Article; the PDF was correct from the time of publication.
Competing interests
: A patent application to the US patent office is pending. D.P.C. has done consulting for Abbvie, Adaptimmune, Agenus, Amgen, Ariad, AstraZeneca, Biocept, Boehringer Ingelheim, Bristol Myers-Squibb (BMS), Celgene, Foundation Medicine, Genentech/Roche, Gritstone, Guardant Health, Inovio, Merck, MSD, Novartis, Palobiofarma, Pfizer, prIME Oncology, Stemcentrx, Takeda, and has unrelated grant support from BMS. The remaining authors declare no competing interests.
